Atomoxetine: Treatment of attention deficit hyperactivity disorder: Beyond stimulants

Drugs of Today

Volumn 40, Issue 5, 2004, Pages 465-473

  Thomason, Christine ^a   Michelson, David ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ATOMOXETINE; CYTOCHROME P450 2D6; CYTOCHROME P450 INHIBITOR; DESIPRAMINE; DEXAMPHETAMINE; FLUOXETINE; IMIPRAMINE; METHYLPHENIDATE; MONOAMINE OXIDASE INHIBITOR; NOMIFENSINE; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PSYCHOSTIMULANT AGENT; QUINIDINE; REBOXETINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL PAIN; APPETITE DISORDER; AREA UNDER THE CURVE; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; COUGHING; DIZZINESS; DRUG ABSORPTION; DRUG EXCRETION; DRUG FATALITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; HEADACHE; HUMAN; IRRITABILITY; NAUSEA; PHARYNGITIS; REVIEW; RHINOPHARYNGITIS; SOMNOLENCE; SUDDEN DEATH; VOMITING;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CLINICAL TRIALS; DRUG INTERACTIONS; HUMANS; PROPYLAMINES; RECEPTORS, ADRENERGIC; TREATMENT OUTCOME;

EID: 3042700080     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2004.40.5.850493     Document Type: Review

References (25)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. American Psychiatric Press, Washington, DC 2000.
2. Murphy, K., Barkley, R.A. Prevalence of DSM-IV symptoms of ADHD in adult licensed drivers: Implications for clinical diagnosis. J Attent Dis 1996, 1: 147-61 (Abstr.).
3. Biederman, J., Newcorn, J., Sprich, S. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 1991, 148: 564-77.
4. Gastfriend, D.R., Biederman, J., Jellinek, M.S. Desipramine in the treatment of adolescents with attention deficit disorder. Am J Psychiat 1984, 141: 906-8.
5. Biederman, J., Gastfriend, D.R., Jellinek, M.S. Desipramine in the treatment of children with attention deficit disorder. J Clin Psychopharmacol 1986, 6: 359-63.
6. Biederman, J., Baldessarini, R.J., Wright, V., Knee, D., Harmatz, J.S. A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy. J Am Acad Child Adolesc Psychiatry 1989, 28: 777-84.
7. Conners, C.K., Casat, C.D., Gualtieri, C.T. et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 1996, 35: 1314-21.
8. Bymaster, F.P., Katner, J., Nelson, D.L. et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacol 2002, 27: 699-711.
9. Spencer, T., Biederman, J., Wilens, T. et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1998, 155: 693-5.
10. Kratochvil, C.J., Bohac, D., Harrington, M., Baker, N., May, D., Burke, W.J. An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder. J Child Adolescent Psychopharmacol 2001, 11: 167-70.
11. Spencer, T., Biederman, J., Heiligenstein, J. et al. An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2001, 11: 251-65.
12. Spencer, T., Heiligenstein, J.H., Biederman, J. et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002, 63: 1140-7.
13. Michelson, D., Allen, A.J., Busner, J. et al. Once-daily atomoxetine treatment for children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled study. Am J Psychiatry 2002, 159: 1896-1901.
14. Michelson, D., Faries, D., Wernicke, J. et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study. Pediatrics 2001, 108: e83.
15. Efficacy trials of atomoxetine for ADHD in children, adolescents and adults. Symposia, San Francisco, CA 2002.
16. Kuhne, M., Schachar, R., Tannock, R. Impact of comorbid oppositional or conduct problems on attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatr 1997, 36: 1715-25.
17. DuPaul, G.J., Power, T.J., Anastopoulos, A.D., Reid, R. ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretations. The Guilford Press, New York, NY 1998.
18. Guy, W. ECDEU Assessment Manual for Psychopharmacology, revised. United States Department of Health, Education and Welfare, Bethesda, MD 1976.
19. Conners, C.K. Conners' rating scales - Revised. Multi-Health Systems Inc., North Towanda, NY 1997.
20. Landgraf, J.M., Abetz, L., Ware, J.E. The CHQ User's Manual, first ed. The Health Institute, New England Medical Center, Boston, MA 1996.
21. Michelson, D., Adler, L., Spencer, T. et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003, 53: 112-20.
22. Conners, C.K., Erhardt, D., Sparrow, E. Conners' Adult ADHD Rating Scales (CAARS). MultiHealth Systems Inc., North Tonawanda, NY 1999.
23. Bech, P., Cialdella, P., Haugh, M.C. et al. Metaanalysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression. Brit J Psychiatr 2000 176: 421-8.
24. Wernicke, J.F. et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 2003, 26: 729-40.
25. Wernicke, J.F., Adler, L., Spencer, T. et al. Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: A prospective placebo-controlled assessment. J Clinical Psychopharmacol 2004, 24: 30-5.